55 Results for "

NSG

" in MedChemExpress (MCE) Product Catalog:
Products (55)

55 Results for "NSG" in MCE Product Catalog:

2
2 Cited Publications
Cat. No.: HY-122895
CAS No.: 2285446-62-8
Purity:  98.10%
Target:  

Apoptosis PDI

Research Areas:  

Cancer

E64FC26 is a potent pan-inhibitor of the protein disulfide isomerase (PDI) family, with IC50s of 1.9, 20.9, 25.9, 16.3, and 25.4 μM against PDIA1, PDIA3, PDIA4, TXNDC5, and PDIA6, respectively. E64FC26 shows anti-myeloma activity .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99222
CAS No.: 876387-05-2
Synonyms: MGA-031; PRV-031

Target:  

CD3

Teplizumab (MGA-031) is a Fc receptor non-binding anti-human CD3 monoclonal antibody. Teplizumab reduces the loss of beta-cell function. Teplizumab can be used in the research of type 1 diabetes .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-168022
CAS No.: 3056388-47-4
Target:  

Aurora Kinase

Research Areas:  

Cancer

CAM2602 is an orally active Aurora A-TPX2 protein−protein interaction inhibitor with a human Kd of 19 nM for Aurora A. CAM2602 increases the proportion of PH3 positive cells while reducing P-T288 Aurora A levels. CAM2602 arrests tumor xenograft growth in mice. CAM2602 can be used for the research of cancer, such as acute T cell leukemia .
loading...
    loading...
Cat. No.: HY-157941
CAS No.: 2267316-76-5
Purity:  99.89%
Synonyms: ART0380
Research Areas:  

Cancer

ART0380 is a potent, selective and orally active ATR kinase inhibitor. ART0380 potently inhibits human ATR-ATRIP complex with an IC50 of 51.7 nM. ART0380 binds the ATP pocket of the ATR-ATRIP complex, blocks ATR-dependent Chk1 serine 345 phosphorylation, and induces cell cycle disorder and DNA damage. ART0380 demonstrates potent and selective antitumor activity in preclinical models with varying types of ataxia-telangiectasia mutated (ATM) gene aberrancy. ART0380 can be used for the research of cancer, such as colorectal cancer and prostate cancer .
loading...
    loading...
Cat. No.: HY-175282
CAS No.: 2748800-08-8
Research Areas:  

Cancer

ASX-173 is an orally active inhibitor of asparagine synthetase (ASNS) (IC50 = 0.113 μM, Ki = 0.4 nM). ASX-173 enhances the anticancer activity of L-asparaginase (ASNase) (HY-P1923). ASX-173 disrupts nucleotide synthesis and induces leukemia cell cycle arrest, apoptosis and autophagy in leukemia cells in combination with ASNase. ASX-173 slows the growth of OCI-AML2 xenografts in combination with ASNase. ASX-173 is indicated for the study of acute lymphoblastic leukemia, acute myeloid leukemia, colorectal cancer, and other cancers .
loading...
    loading...
Cat. No.: HY-P99199
CAS No.: 946415-64-1
Synonyms: NI-0401

Target:  

CD3

Foralumab (NI-0401) is a potent, orally active human monoclonal antibody targeting the CD3. Foralumab modulates immune responses by human cells in NSG mice that were reconstituted with human hematopoietic stem cells .
loading...
    loading...
Cat. No.: HY-174143
CAS No.: 1111188-09-0
Target:  

Apoptosis

Research Areas:  

Cancer

EXO1-IN-1 is a human exonuclease 1 (EXO1) inhibitor (IC50 = 15.7 μM). EXO1-IN-1 inhibits DNA end resection, promotes the accumulation of DNA double-strand breaks, and triggers S-phase polyamylation. EXO1-IN-1 induces apoptosis (Apoptosis) in BRCA1-deficient breast cancer cells. EXO1-IN-1 suppresses the growth of BRCA1-deficient breast cancer xenografts. EXO1-IN-1 can be used in research related to BRCA1-deficient breast cancer .
loading...
    loading...
Cat. No.: HY-151902
CAS No.: 2595365-41-4
Purity:  98.05%
Target:  

PROTACs JAK

Research Areas:  

Cancer

SJ988497 is a PROTAC JAK2 degrader. SJ988497 potently inhibits CRLF2-rearranged (CRLF2r) cell proliferation and degrades the CRBN neosubstrate GSPT1. SJ988497 consists of a Ruxolitinib (HY-50856) derivative, linker, and CRBN ligand Pomalidomide. SJ988497 can be used in the research of acute lymphoblastic leukemia (ALL) .
loading...
    loading...
Cat. No.: HY-168016
CAS No.: 3058483-58-9
Target:  

PROTACs YAP

Research Areas:  

Cancer

PROTAC YAP degrader-1 is a VHL-recruiting PROTAC degrader (DC50=8.2 μM) and antiproliferative agent that targets YAP. PROTAC YAP degrader-1 recruits the E3 ligase VHL and binds to VHL to form a ternary complex containing YAP. PROTAC YAP degrader-1 inhibits the nuclear localization of YAP in cancer cells, reduces YAP/TEAD-mediated transcription, and induces TAZ protein degradation. PROTAC YAP degrader-1 reduces the oncogenic activity of YAP and exerts antiproliferative effects in the Huh7 xenograft mouse model. PROTAC YAP degrader-1 can be used for the research of hepatocellular carcinoma and mesothelioma .
loading...
    loading...
Cat. No.: HY-174979
CAS No.: 3084407-00-8
Dac590 is an orally active and selective obesity-associated protein (FTO) inhibitor with an IC50 of 6.06 nM. Dac590 shows highly selective over ALKBH5 and ALKBH3. Dac590 suppresses oncogenic FTO signaling, induces myeloid differentiation, G1-phase cell cycle arrest, and apoptosis in acute myeloid leukemia (AML) cells. Dac590 inhibits xenograft tumor growth and prolongs survival in acute myeloid leukemia mouse models with no observed toxicity. Dac590 can be used for the research of AML .
loading...
    loading...
Cat. No.: HY-143889
CAS No.: 2375554-02-0
Purity:  98.82%
Target:  

CDK

Research Areas:  

Cancer

Senexin C is a selective and orally active CDK8/19 inhibitor. Senexin C shows a strong tumor-enrichment pharmacokinetic (PK) profile and tumor-pharmacodynamic (PD) marker responses. Senexin C inhibits the growth of MV4-11 leukemia cells with good tolerability .
loading...
    loading...
Cat. No.: HY-P99252
CAS No.: 1116433-11-4
Synonyms: Anti-Human CD6 Recombinant Antibody

Target:  

CD6

Research Areas:  

Infection Inflammation/Immunology

Itolizumab (Anti-Human CD6 Recombinant Antibody) is a humanized recombinant anti-CD6 monoclonal antibody (MAb) targeting the extracellular SRCR distal domain 1 of CD6. Itolizumab reduces T-cell proliferation and inhibits the production of pro-inflammatory cytokines, such as INF-γ, TNFα and IL-6. Itolizumab can be used in the research of psoriasis, rheumatoid arthritis (RA), COVID-19 .
loading...
    loading...
Cat. No.: HY-P99884
CAS No.: 2206792-50-7
Synonyms: PF-06801591

Target:  

PD-1/PD-L1

Research Areas:  

Inflammation/Immunology Cancer

Sasanlimab is a humanized IgG4 isotype anti-PD-1 antibody. Sasanlimab blocks PD-1 interaction with PD-L1/PD-L2, reverses PD-1-mediated inhibitory T-cell signaling, augments T-cell proliferation and cytokine production. Sasanlimab inhibits colon adenocarcinoma tumor growth, and accelerates graft-versus-host disease incidence via enhanced T-cell activity. Sasanlimab can be used for the research of cancer, such as bladder cancer and colon adenocarcinoma .
loading...
    loading...
Cat. No.: HY-P2989
CAS No.: 9014-19-1
Target:  

Endogenous Metabolite

Research Areas:  

Metabolic Disease Cancer

Pyruvate carboxylase is a key mitochondrial anaplerotic enzyme that catalyzes the conversion of pyruvate to oxaloacetate. Pyruvate carboxylase not only maintains tricarboxylic acid cycle activity and redox homeostasis, but also drives hepatic gluconeogenesis and fatty acid synthesis. The activity of Pyruvate carboxylase is upregulated in insulin-resistant states, exacerbating hepatic glucose production. Pyruvate carboxylase also shows significantly enhanced expression in early-stage non-small cell lung cancer (NSCLC). Pyruvate carboxylase promotes tumor proliferation by supporting nucleotide and lipid synthesis, and its functional deficiency cannot be compensated by glutaminolysis. Pyruvate carboxylase can be used in the research of prediabetes type 2 and NSCLC .
loading...
    loading...
Cat. No.: HY-109179
CAS No.: 1628870-27-8
Purity:  99.06%
Synonyms: TP-0184
Itacnosertib (TP-0184) is the inhibitor for FLT3, ACVR1 (ALK2, IC50=8 nM) and JAK2 (IC50=8540 nM). Itacnosertib exhibits anti-leukemic activity .
loading...
    loading...
Cat. No.: HY-115581A
CAS No.: 118675-87-9
Purity:  ≥97.0%
Synonyms: Deoxythymidine 3′,5′-diphosphate tetrasodium; pdTp tetrasodium
Target:  

Apoptosis MicroRNA

Research Areas:  

Cancer

Thymidine 3',5'-diphosphate (Deoxythymidine 3′,5′-diphosphate) tetrasodium is a selective inhibitor of staphylococcal nuclease and tudor domain containing 1 (SND1, the MicroRNA regulatory complex RISC subunit) and [3,5- 2H2] tyrosyl nuclease. Thymidine 3',5'-diphosphate tetrasodium has anti-tumor activity and can also be used as a catalyst in biochemical reactions .
loading...
    loading...
Cat. No.: HY-175370
Target:  

PROTACs RIP kinase

Research Areas:  

Cancer

PROTAC RIPK1 Degrader-1 is a selective RIPK1 PROTAC degrader. PROTAC RIPK1 Degrader-1 degrades RIPK1 in multiple cancer cell lines (e.g., A375, B16F10 cells). PROTAC RIPK1 Degrader-1 enhances the anti-cancer effect of radiotherapy in syngeneic and humanized mouse models. PROTAC RIPK1 Degrader-1 can be used to study cancers such as melanoma .
loading...
    loading...
Cat. No.: HY-122895A
CAS No.: 2285446-67-3
Purity:  98.09%
Target:  

Apoptosis PDI

Research Areas:  

Cancer

(E/Z)-E64FC26 is a mixture complex of E-E64FC26 and Z-E64FC26. E64FC26 (E-E64FC26) is a potent pan-inhibitor of the protein disulfide isomerase (PDI) family, with IC50s of 1.9, 20.9, 25.9, 16.3, and 25.4 μM against PDIA1, PDIA3, PDIA4, TXNDC5, and PDIA6. E64FC26 shows anti-myeloma activity .
loading...
    loading...
Cat. No.: HY-P6825
CAS No.: 2790413-59-9
Synonyms: LY4181530; PSMA-62
Target:  

PSMA

Research Areas:  

Cancer

PNT2001 (LY4181530) is a high-affinity PSMA-targeted radiopharmaceutical ligand precursor. natLu-PNT2001 has an IC50 of 3.1 nM against PSMA. PNT2001 is applicable for PSMA targeting, radiopharmaceutical ligand delivery, and prostate cancer-related research .
loading...
    loading...
Cat. No.: HY-P991176
Synonyms: RO7443904

Target:  

CD19 CD28

Research Areas:  

Cancer

RG-6333 is a bispecific agonist targeting CD19 and CD28. RG-6333 specifically recognizes and binds to the CD19 antigen on the surface of B-cell malignancies to locate tumor cells. RG-6333 activates T cells by binding to CD28, overcoming activation barriers to enhance anti-tumor immunity. RG-6333 can be used in the study of relapsed/refractory non-Hodgkin's lymphoma. The recommended isotype control is human IgG1 kappa, isotype control (HY-P99001) .
loading...
    loading...